ImmunityBio, Inc. IBRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$632.8M-388% | -$61.96M-4.7% | -$67.27M+21.5% | -$92.57M+31.2% | -$129.67M+3.3% | ||
| $4.38M+14.4% | $3.87M-6.6% | $3.95M-11.3% | $3.88M-11.9% | $3.83M-15.9% | ||
| $8.17M-14.3% | $8.75M-3.2% | $8.88M+18.5% | $9.65M+0.1% | $9.54M+15.4% | ||
| -$75.36M+12.3% | -$70.38M+17.3% | -$68.91M+30.2% | -$79.75M+20.5% | -$85.91M+19.7% | ||
| $1.78M+58.4% | $903K-57.2% | $741K-73.5% | $1.08M+49.3% | $1.12M-11.1% | ||
| -$31.65M-867% | —— | -$181.36M— | -$16.14M+68.7% | $4.13M+112% | ||
| $61K— | —— | —— | —— | $0— | ||
| $868K— | —— | —— | —— | $0— | ||
| $223.93M+22,903% | $54.89M-48.7% | $173.52M+1,014% | $172.81M+16.1% | -$982K-110% | ||
| $117.04M+241% | —— | -$76.81M-323% | —— | -$82.77M+37.5% | ||
| -$77.14M+11.4% | -$71.28M+18.3% | -$69.65M+31.4% | -$80.83M+20.0% | -$87.03M+19.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
